CWE held ‘Lancang Mekong Green Course’ Open Day to celebrate the 10th anniversary of the Nam Ngiep 2 Hydropower Station ACN Newswire

CWE held ‘Lancang Mekong Green Course’ Open Day to celebrate the 10th anniversary of the Nam Ngiep 2 Hydropower Station

Vientiane, Laos, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - To celebrate the 10th anniversary of the commissioning and operation of the Nam Ngiep 2 Hydropower Station in Laos, China International Water & Electric Corp. (CWE), a subsidiary of China Communications Construction Company (CCCG), held “Lancang Mekong Green Course” Open Day event from July 4 to 5, 2025. The event drew wide participation from students and faculty of the National University of Laos, government representatives at various levels, and residents from surrounding communities, who came together to witness the station’s achievements over the past decade.Nam Ngiep 2 is the second Build-Own-Operate-Transfer (BOOT) hydropower project developed by the CWE in Laos. With a total installed capacity of 180 MW, the station began commercial operation in October 2015. Over the past 10 years, it has generated over 4.2 billion kilowatt-hours of electricity, supplying power to approximately 780,000 people and making a significant contribution to the energy stability of northern Laos. In 2022, it was awarded the Second-Class Labor Medal, a national honor of Laos.This Open Day event was based on the CWE’s “Lancang Mekong Green Course” brand project, focusing on local university students and youth. Five thematic modules were designed around the station’s 10th anniversary: Practical Class, Research Class, Science Class, Activity Class, and Culture Class. A photo exhibition titled “10 Years of Development of Nam Ngiep 2” was also set up, showcasing the station’s construction milestones, operational management, environmental protection efforts, and community engagement practices.Led by Chinese and Lao engineers, participants engaged in immersive learning through practical, research, and science classes. These sessions helped local youth gain a hands-on understanding of hydropower generation, the multifunctional role of water conservancy projects, and the technological innovations within China-Laos joint projects. A “Decade Together” sharing session featured long-serving employees from both countries who shared personal stories of growing alongside the project—encouraging young students to pursue careers in clean energy.A student from the Faculty of Engineering at the National University of Laos, said:“This event taught me so many things beyond the textbooks. I saw firsthand how the station operates and felt the commitment of Chinese enterprises to social responsibility and ecological protection. It’s an honor to witness this important 10-year milestone in person.”In the Activity Class, the station worked with the local government to organize eco-friendly activities such as tree planting and fish fry release. Around 2,000 saplings—including mango and longan—were planted, and approximately 100,000 juvenile fish such as tilapia and crucian carp were released, reinforcing the station’s commitment to green development and community engagement. The government of Phaxay awarded the station an “Ecological Protection Honor Certificate for the Mekong River Basin.” County Chief Khamla Keodavanh commented:“Nam Ngiep 2 not only provides stable and clean power to Laos, but also protects the river basin's ecosystem through activities like tree planting and fish release. This honor is the best recognition of its commitment to sustainable development.”During the Culture Class, students were invited to experience traditional Chinese cuisine. Under the guidance of the station’s staff, they learned to wrap sticky rice dumplings (zongzi), roll rice balls (tangyuan), make dumpling wrappers, and prepare green rice cakes (qingtuan). The festivities also included a Chinese hotpot meal and a celebratory cake to mark the station’s 10th “birthday”, creating a joyful and festive atmosphere.Throughout the event, students actively posted their experiences and “highlight moments” on international social media platforms, attracting widespread attention and engagement from local youth. The event-related content reached over 350,000 views online. Local media outlets also covered the event live.Over the years, the hydropower station has brought tangible economic, social, and environmental benefits to local communities by building infrastructure, supporting resettlement villages, and preserving cultural heritage. Village chief from Poung Village shared:“Ten years ago, due to our remote location and difficult terrain, our village was the only one in Xiengkhuang Province without electricity. With continuous support from Nam Ngiep 2, we finally got power. Last year, the station even helped us build our first primary school. Thanks to the station, our children now have a classroom where they can learn in peace. The station has not only brought light to our village, but also hope for the future.”Serving as a platform for cultural exchange, the “Lancang Mekong Green Course” Open Day vividly showcased the decade-long journey and accomplishments of the China-Laos joint project. It also deepened local youth’s understanding of the green energy sector and opened a new chapter in regional energy cooperation across the Lancang-Mekong region.Company: China International Water & Electric CorporationWebsite: https://english.cwe.cn/ Contact: Xiao RanTEL: +86 13146100749Email: xiaoran@ccccltd.cn Copyright 2025 ACN Newswire via SeaPRwire.com.
More
品創控股授購股權 訂首三季完成7,500萬港元盈利目標 ACN Newswire

品創控股授購股權 訂首三季完成7,500萬港元盈利目標

香港,2025年7月28日 - (亞太商訊 via SeaPRwire.com) - 品創控股有限公司(「品創控股」或「公司」,連同其附屬公司統稱為「集團」;股份代號:8066)公佈向集團兩家全資附屬公司山西動創數娛科技集團有限公司(「山西動創」)及賽博幻境(香港)有限公司(「賽博幻境」)的10名合資格僱員(「承授人」)授出購股權,以獎勵僱員在推動集團業務持續增長及實現卓越業績的重大貢獻。同時,透過授予購股權,能進一步將僱員的利益與集團的長遠發展目標緊密結合,激勵僱員積極參與集團的未來發展,提升整體競爭力及經營表現,並鞏固僱員長期為集團服務的承諾及意願。購股權計劃合共授出52,500,000份購股權,每份購股權賦予承授人權利認購一股股份,行使期為授出日起計十年。值得一提的是,是次授出之購股權的行使條件與山西動創及賽博幻境的業績掛鈎,兩家公司截至2025年9月30日止九個月的未經審核稅前溢利總額需不少於7,500萬港元,此舉反映集團對兩家附屬公司未來表現及業績達標的高度信心。關於品創控股有限公司品創控股有限公司的使命是妥善運用公司所獲得的資本與獨特投資機會,為股東提供穩定的優渥收入與獲利。品創由三個主要事業部門組成,包括智能卡製造服務、投資服務與資源回收投資,主要業務為生產及銷售智能卡、提供定製智能卡應用系統、提供財務及管理諮詢服務、廢舊金屬銷售及貿易、以及媒體與娛樂行業之投資。公司的總部位於香港,旗下控股公司與投資則遍佈大中華地區。關於山西動創數娛科技集團有限公司山西動創數娛科技集團有限公司(前稱「海南動創數娛科技集團有限公司」)從事運營泛娛樂數字生態系統會員電子商務平台,平台主要提供帶私域流量的娛樂電子商務,包括提供數字產品及服務。關於賽博幻境(香港)有限公司賽博幻境(香港)有限公司(前稱「智能生產管理系統有限公司」)從事提供人工智能語音服務。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More

OMS Energy Recorded Significant Profits Growth in 2025FY, Roth Capital Rating it “Buy” with a Potential 40% Upside TP

HONG KONG, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - The successfully pass of U.S. President Donald Trump's One Big Beautiful Bill Act is expected to have a crucially impact on America's energy structure. A key focus of the entire Act is that the U.S. federal government will significantly eliminate subsidies for green energy such as wind power, solar energy, and electric vehicles in the future, while increasing subsidies for fossil energy. In other words, America's energy structure will return to the old era, that is, the golden era of the U.S. dollar which is the dominant global settlement currency. Therefore, investor should pay more attention on such situation and bet on oilfield production infrastructure manufacturers and refineries in the energy sector, rather than on upstream energy companies, whose business performance are closely related to international oil prices.Recently, Roth Capital initiated a research report on OMS Energy Technologies (NASDAQ: OMSE), a Singapore-based company focusing on the R&D and production of surface wellhead systems (SWS) and oil country tubular goods (OCTG). Roth Capital initiated the company "Buy" rating with a 12-month target price of US$10. On 24 July, OMSE announced its 2025 fiscal year earnings results, and its stock price surged by more than 8% after the results was announced, closing at US$7.18, which still has nearly 40% upside potential compared to its target price.OMSE's business mainly involves the exploration and production infrastructure for the oil and natural gas industry, namely SWS and OCTG. Its products are widely used in onshore and offshore oilfield exploration and production (E&P) activities in the Asia-Pacific region, the Middle East, and North Africa. Currently, the company has 11 manufacturing facilities strategically located in oil and gas service hubs across 6 jurisdictions. It also has finishing facilities near some of its top end-users' E&P operations, including in Saudi Arabia where its largest client Saudi ARAMCO Oil is located.On 24 July, OMSE announced its full year earnings results ended March 31, 2025. The company recorded revenue of approximately US$204 million with operating profit of approximately US$60 million. Both marked a year-on-year significant growth. Besides, the company has ample cash on hand, reaching US$75.8 million as of March 31, 2025.Notably, due to a restructuring carried out before 2023, where the management team conducted a buyout from major shareholder, the company booked a NAV premium of US$49.4 million according to international accounting standards in 2024FY, resulting in operating profit of over $80 million recorded for the 2023/2024 fiscal year. Excluding the one-off NAV premium, operating profit in fiscal year 2024/2025 is US$59.9, showing a significant year-on-year increase from US$43.4 million in fiscal year 2023/2024.Saudi Aramco Oil orders provide 10-year revenue streamAccording to Roth Capital's forecast, OMSE will maintain a remarkable growth in the next few years. This is mainly due to the company's acquisition of new orders in Angola and Thailand, marking significant progress in expanding its global business. An even greater growth driver comes from the 10-year supply agreement signed by OMSE with Saudi ARAMCO Oil (TADAWUL: 2222) at the beginning of 2024, which is expected to generate US$120 million to US$200 million in annual income. In the future, there is a good chance to further expand its business coverage or market share through mergers and acquisitions, continuously enhancing profitability. The company has invested $1.1 million in R&D for metal seals used in high-pressure and high-temperature gate valves, and has completed the first phase of the project. This is expected to become a new stream of income in the future.In summary, the company has strong fundamentals. Additionally, with the United States, which accounted for over 15.6% of global fossil energy demand in 2023, returning to the era of conventional energy, it is expected not only to drive the balance between supply and demand, support international oil prices, but also to boost oil production, benefiting many oilfield E&P infrastructure providers such as OMSE.Finally, the United States' attempt to consolidate the dollar's dominant position in the international settlement system by expanding conventional energy transactions is bound to be a long-term trend. Goldman Sachs expects Brent crude oil prices to remain at $76 per barrel in 2025, which further reflects this potential U.S. influence. Whether in the short or medium term, the investment value of oilfield E&P infrastructure stocks is steadily increasing. According to Bloomberg data, the average P/E ratio of the global oilfield service and related oilfield equipment industry is 15x, while OMSE's current P/E ratio is only 5x, reflecting a significant lag in valuation. Finally, it is worth mentioning that the company has sufficient cash on hand and a stable business, and it is not ruled out that it will pay dividends in the future, which deserves more attention. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Saudi Electricity Company Achieves 30% Increase in 2025 Sustainability Rating Compared to 2024, According to S&P ACN Newswire

Saudi Electricity Company Achieves 30% Increase in 2025 Sustainability Rating Compared to 2024, According to S&P

RIYADH, KSA, July 27, 2025 - (ACN Newswire via SeaPRwire.com) - The Saudi Electricity Company (SEC) has achieved a significant milestone in its Environmental, Social, and Governance (ESG) performance, as evaluated by S&P Global. The company scored 65 out of 100, marking a 30% increase compared to its 2024 score, and an 85% improvement over its 2023 rating. This accomplishment highlights SEC's strategic progress and reinforces its position as a regional leader and a benchmark for sustainable excellence in the energy sector. Notably, SEC's score exceeds the global utilities sector average of 39 points by 66%, demonstrating its strong commitment to sustainable development. The rating reflects SEC's comprehensive institutional commitment to sustainability, driven by effective governance frameworks, ambitious strategies, and tangible improvements in environmental and social performance. SEC also showcased proactive disclosure aligned with leading international sustainability reporting standards. This progress further underscores SEC's alignment with Saudi Vision 2030, particularly in advancing sustainable energy, enhancing transparency, strengthening investor confidence, and adopting global ESG best practices. SEC reaffirmed its commitment to continuously improving its ESG performance by deeply embedding sustainability across all operations, positioning itself as a trusted and responsible energy provider both regionally and globally.Contact InformationSaudi Electricity Company (SEC)Media Relations Departmentalkahrabacare@se.com.saUnified Call Center: 920000222 Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Theinvestmedia.com 提供獨家開戶優惠與深度教學,賦能投資者精準決策 ACN Newswire

Theinvestmedia.com 提供獨家開戶優惠與深度教學,賦能投資者精準決策

香港, 2025年7月26日 - (亞太商訊 via SeaPRwire.com) - 作為香港及亞洲其中一個領先的股票開戶優惠比較及實戰投資教學媒體平台,https://theinvestmedia.com 今日隆重宣布,其網站已獨家更新並推出全面優化的「券商開戶優惠」專題頁面,同時發佈一系列由資深專家團隊親身撰寫的「券商開戶及平台使用實戰教學」。此舉旨在透過即時、具體且高度可信賴的資訊,賦能廣大個人投資者,特別是那些尋求券商開戶優惠最佳方案及平台實用操作教學的用戶,確保其在瞬息萬變的全球金融市場中,能夠做出最明智、最有效率的決策。Theinvestmedia.com 核心團隊由超過八年金融投資實戰經驗的資深投資銀行家、證券商管理層及註冊會計師 (CPA) 組成。團隊深知金融資訊的專業性與即時性對於投資決策的關鍵影響。本次針對券商開戶教學與獨家開戶優惠的深度更新,正是團隊將豐富經驗轉化為實際用戶價值的體現。獨家券商開戶優惠,實測與深度教學解析為回應市場對券商開戶優惠的高度關注,Theinvestmedia.com 不僅詳細羅列了當前市場上所有公開的開戶優惠,更獨家公開與不同持牌金融券商合作夥伴聯手推出的開戶優惠(詳情請參閱 Theinvestmedia.com 官方網頁)。這些開戶優惠不僅極具吸引力,團隊更在教學指南中深度解析其申領流程、條款細則及如何獲得最多開戶優惠價值,旨在幫助用戶清晰掌握,避免任何潛在困惑。團隊的目標是讓用戶在選擇不同頂級券商開戶時 (例如 IB開戶優惠、富途、老虎、OSL等),能獲得最透明、最全面的開戶優惠資訊。實戰指南:從圖解券商開戶流程到進階平台使用教學及策略除了開戶優惠優惠比較,本次更新的另一大亮點是一系列經團隊實測與驗證的券商開戶及平台使用實戰教學。這些教學指南深入淺出地涵蓋:圖解最詳細的開戶流程及技巧: 針對常見開戶疑問與操作難點,提供圖解步驟與提示 (例如圖解IB開戶)。不同證券平台功能深度導覽: 介紹其多元投資產品(例如美股、港股、日股、外匯、債券、ETF 等)的交易介面介紹與常用功能。 外幣兌換匯率比較: 針對美元兑港元、日元兑港元、英鎊兑港元、歐元兑港元、加元兑港元、澳元兑港元、人民幣兑港元、新加坡幣兑港元及其他外幣的兌換匯率比較、還有不同貨幣的出金、入金的實用建議。特定交易工具與策略應用: 分享資深團隊在實際操作中如何利用券商平台進行有效的風險管理與策略執行。每一篇指南都經過多源頭詳盡資料收集,並只引用持牌券商官方報告及多次開戶測試等權威數據來源。在發佈前,所有內容皆會歷經嚴格的多重團隊內部核實及資深合規顧問的專業審閱,確保資訊的權威性與百分百準確性。以客為本建立信任:用戶回饋與客戶服務支援Theinvestmedia.com 堅持以用戶為中心,平台的信任度建立在透明與快速回應之上。平台已有多名電子郵件訂閱用戶並持續增長,其積極的互動與回饋廣受用戶好評,證明了網站內容的實際價值。Theinvestmedia.com更設有專業客戶服務團隊,可透過網站或電郵(hello@theinvestmedia.com)為用戶提供個人化的疑難解答,確保用戶如對券商開戶優惠、平台使用攻略或任何教學相關資訊有任何疑問,都能在辦公時間內獲得即時、專業的支援。平台創始團隊表示:「我們深信,真正有價值的金融資訊必須是實用、即時且可驗證的。這次針對券商開戶的獨家開戶優惠與實戰教學指南,正是我們踐行這一理念的最新成果。我們不僅提供『魚』,更致力於教導『漁』,賦能每位投資者自信地駕馭全球金融市場。」Theinvestmedia.com 誠摯邀請所有對券商開戶優惠、證券平台操作及專業投資知識感興趣的讀者,立即瀏覽 Theinvestmedia.com,探索這些由金融專家經驗淬鍊而成的獨家資源,開啟您的穩健投資學習之路。關於 Theinvestmedia.comTheinvestmedia.com 是一個專注於為個人投資者提供開戶優惠比較及專業投資教學資訊的線上媒體平台,由一支具備逾八年金融實戰經驗的專家團隊營運。網站內容涵蓋美股、港股、日股、外匯、債券、ETF 等多元投資主題,並特別針對開戶優惠比較、開戶教學及股票戶口操作 (例如IB開戶優惠) 提供深入教學及解析。Theinvestmedia.com 致力於簡化複雜的金融概念,幫助投資者建立堅實的投資知識基礎,做出明智的理財決定。所有內容均為實際經驗分享及向公眾作為教學用途,平台不會提供任何投資建議。傳媒及讀者查詢:Theinvestmedia.com 公關部電子郵件: hello@theinvestmedia.com網址: https://theinvestmedia.comFacebook: https://www.facebook.com/theinvestmediaX.com: https://x.com/theinvestmediaSOURCE: Theinvestmedia Copyright 2025 亞太商訊 via SeaPRwire.com.
More
維立志博於聯交所主板成功上市 ACN Newswire

維立志博於聯交所主板成功上市

香港,2025年7月25日 - (亞太商訊 via SeaPRwire.com) - 下一代肿瘤免疫疗法的领跑者 - 南京維立志博生物科技股份有限公司(「維立志博」或「公司」,股份代號:9887.HK),宣佈於香港聯合交易所有限公司(「香港聯交所」)主板上市,股票代號爲9887.HK。維立志博此次發售每手買賣單位100股H股,最終發行價為每股35.00港元,處於31.60港元至35.00港元價格區間的上限。基礎發行股數為36,862,500股H股(經計及發售量調整權獲悉數行使及視乎超額配股權行使與否而定),其中香港發售股份數目為16,027,200股H股(經重新分配後予以調整),國際發售股份數目為20,835,300股H股(經計及發售量調整權獲悉數行使、經重新分配後予以調整及視乎超額配股權行使與否而定)。超額配售權方面,超額分配的發售股份數目(經計及發售量調整權獲悉數行使)為12,821,700股H股,均來自國際發售。募集資金規模方面,算上綠鞋後總發行規模可達1.89億美元。融资达1.89億港元 18A最强基石阵容领跑維立志博此次IPO招股引入基石投资者9席,合共認購約5.42億港元。基石投资者名单集结多家头部医疗专业基金及长线机构,既有國際知名醫療專業基金OrbiMed、TruMed,也包含國內頭部公募基金易方达基金;既包括活躍香港二級市場的創新藥投資基金Foresight Funds、Sage Partners,更不乏腾讯、高毅等長線價值的國內頭部著名私募基金。此外,還有老股東著名醫藥專業投資基金正心谷资本和汉康资本的加倉。摩根士丹利、中信证券為本次發行之聯席保薦人。根據公司策略,維立志博本次IPO募集所得資金淨額的約65.0%擬將用於臨床階段候選藥物正在進行及計畫進行的臨床開發和監管事務;約15.0%將用於推進臨床前資產、擴展現有管線並優化技術平台;約10.0%將主要用於提升生產能力,其次用於候選藥物獲批銷售後的商業化;以及約10.0%將用於營運資金及一般企業用途。公司於2012年成立,是一家臨床階段生物科技公司,專注於腫瘤、自身免疫性疾病及其他重大疾病新療法的發現、開發及商業化。公司已建立多元化的產品組合,包括4款核心及主要產品,各款產品組合均處於全球臨床進度領先的候選藥物之列(不論於其各自藥物類別或針對相同靶點的藥物當中)。其中,核心產品LBL-024由公司內部開發,是一款處於註冊臨床階段的PD-L1與4-1BB雙特異性抗體,其為全球首個已處於註冊臨床階段的靶向4-1BB受體的療法,亦有望成為治療晚期肺外神經內分泌癌的首款獲批藥物。維立志博的核心業務模式是自主發現、開發及商業化腫瘤免疫療法。公司通過重點佈局腫瘤免疫2.0(IO 2.0)、T細胞銜接器(TCE)和抗體偶聯藥物(ADC)三大領域,積極探索多領域組合療法,在全球腫瘤治療領域建立了差異化競爭優勢。截至目前,維立志博的腫瘤管線共12款產品,分別為3款單克隆抗體、5款雙特異性抗體、3款抗體偶聯藥物(ADC)以及1款雙特異性融合蛋白。此外,維立志博還佈局針2款自身免疫性疾病,包括1款雙特異性融合蛋白及1款三特異性抗體。技術平台持續創新維基 多款核心產品顯露行業頭部潛質公司採用科學驅動的研發方法,開發了包括LeadsBody™平台(CD3 T-cell engager平台)、X-body™平台(4-1BB engager平台)、Linker-payload(ADC技術平台)在內的專有技術平台。技術平台是公司持續創新的基石,並已通過雙特異性抗體組合的臨床結果得到驗證。LeadsBody™平台為靶向CD3的雙特異性抗體的開發提供了堅實的技術支援,通過對TCE分子設計進行多樣化修改,可精細調節TCE對CD3及腫瘤相關抗原的親和力,通過精准的空間位阻分子結構設計,做到只在腫瘤微環境中條件啟動,從而有效減少細胞因數風暴風險,降低系統性毒性。通過LeadsBody™平台量身定制的分子定位及空間排列能優化療效與安全性之間的平衡,減少與毒性相關的治療中斷,延長治療持續時間,提高患者的生活品質。基於這一平台,維立志博已在更具市場前景的實體瘤治療領域建立了先發優勢,截至目前,已佈局6款差異化TCE管線產品,成功建起覆蓋血液瘤、實體瘤及自免三大疾病領域的TCE產品矩陣。血液瘤領域- LBL-034:GPRC5D/CD3雙特異性抗體,用於治療多發性骨髓瘤。- LBL-043:LILRB4/CD3雙特異性抗體,用於治療急性髓系白血病及多發性骨髓瘤。實體瘤領域- LBL-033:MUC16/CD3雙特異性抗體,用於治療MUC16高表達的實體瘤,特別是卵巢癌、宮頸癌及子宮內膜癌等婦科癌症。- LBL-054:CDH17/CD3 T-cell engager,在結直腸癌、胃癌、胰腺導管腺癌、神經內分泌癌等廣泛適應症中有良好應用前景。- LBL-058:靶向DLL3的TCE雙特異性抗體-藥物偶聯物,全球首創的TCE ADC新品類產品,在DLL3表達陽性的小細胞肺癌、神經內分泌腫瘤治療中具有良好前景。自免領域- LBL-051:全球首創CD19/BCMA/CD3三特異性抗體,可有效阻斷B細胞及漿細胞產生自體抗體,同時有可能持續抑制B細胞過度啟動、分化及轉化為漿細胞,從而有望透過調節B細胞調節的多個方面實現卓越的治療效果。目前已與知名生物技術風險投資公司Aditum Bio成立的NewCo達成合作。X-body™平台利用先進的抗體工程技術,以2:2結構創造差異化的雙特異性抗體,其首個產品LBL-024開創性地採用PD-L1/4-1BB雙特異性抗體設計,獨特的分子設計使LBL-024能夠做到在腫瘤微環境中條件啟動4-1BB的激動劑作用,克服有關4-1BB系統性毒性尤其是肝毒性這一主要障礙,降低全身毒性的風險,成功攻克了4-1BB這個腫瘤免疫明星靶點開發的行業難題,成為全球首個也是唯一一款進入註冊臨床階段的4-1BB抗體藥。 值得特別指出的是,4-1BB作為激動劑,能夠重新啟動衰竭的T細胞並大量擴增,因此特別適合治療PD-1/PD-L1耐藥的或無效的所謂冷腫瘤。公司目標為發展成為一家綜合性生物技術公司,迄今為止,公司已經建立從早期篩選及發現、臨床前研究、臨床開發、CMC到中試生產的整個藥物開發過程中的所有基本功能。該等綜合能力凸顯公司在藥物開發活動的可擴展性及可複製性,使其能夠持續推進候選藥物的開發。利用該等各不相同但相互關聯的功能之間的協同作用,在短短三年內即實現從靶點選擇至提交IND的高效藥物開發流程,根據弗若斯特沙利文的資料,此優於行業約5至6年的平均水平。作為自主開發的補充,維立志博亦與第三方合作進行候選藥物的臨床開發及商業化,以通過對外授權許可、商業化合作或其他戰略合作更好地把握市場機遇。隨著臨床資產接近商業化上市,公司可能會考慮建立具商業規模的生產設施,並透過合作及內部銷售團隊加強商業化能力。南京維立志博生物科技股份有限公司(「維立志博」或「公司」;股份代號:9887.HK)是一家臨床階段的生物科技公司,公司成立於2012年,致力於創新療法的發現、開發及商業化,以滿足中國及全球在腫瘤、自身免疫性疾病及其他重大疾病方面未獲滿足的醫療需求。公司作為下一代腫瘤免疫療法的領跑者,擁有涵蓋14款創新候選藥物的差異化創新管線,其中6款已成功進入臨床階段,4款主要產品均處於全球臨床進度領先的候選藥物之列。公司採用科學驅動的研發方法,已成功建立涵蓋抗體發現及工程、體內及體外療效評估以及成藥性評估的綜合研發能力。公司亦開發了包括LeadsBody™平台(CD3 T-cell engager平台)、X-body™平台(4-1BB engager平台)在內的專有技術平台。技術平台是公司持續創新的基石,並已通過雙特異性抗體組合的臨床結果得到驗證。公司成功建立起了在早期研發、轉化醫學、臨床開發、CMC以及業務拓展方面無縫銜接的自主能力。公司候選藥物的創新性質及競爭優勢,配合其全球視野、積極主動的策略及高效的臨床驗證使公司成為備受歡迎的合作夥伴。此新聞稿由博達浩華國際財經傳訊集團代表南京維立志博生物科技股份有限公司發佈。如有垂詢,請聯絡︰博達浩華國際財經傳訊集團馮嘉莉女士(852)31506763kelly.fung@h-advisors.global王佩女士(86)13520068960evie.wang@h-advisors.global Copyright 2025 亞太商訊 via SeaPRwire.com.
More

OMS能源2025財年業績增長強勁 Roth Capital評級買入潛在升幅40%

香港,2025年7月25日 - (亞太商訊 via SeaPRwire.com) - 美國總統特朗普的大而美法案通過,市場預期將對美國能源結構造成重大影響。整個法案重點之一是美國聯邦政府未來將取消風電、太陽能、電動車等綠色能源補貼,但同時擴大石化能源補貼。換言之,美國能源結構將重返舊時代,亦即是美國的黃金美元時代。亦因此,大家都要看清形勢,押寶能源板塊中的基礎設備商及煉油廠,而不是與國際油價息息相關的上游能源股。近期,Roth Capital發表了研報,首次覆蓋總部位於新加坡、專注地面井口系統(SWS)和石油專用管材(OCTG)研發生產的OMS Energy Technologies (NASDAQ: OMSE),評級「買入」,目標價10美元。OMSE於7月24日公布2025財年業績,而股價於業績公布後大升逾8%,收報7.18美元,較目標價仍具有近40%的上行空間。OMSE的業務主要是生產用於石油和天然氣行業的勘探開發基礎設施,即地面井口系統(SWS)和石油專用管材(OCTG),產品廣泛覆蓋亞太地區、中東和北非地區的陸上和海上勘探開發活動。目前,公司在6個司法轄區設有11個位於油氣服務中心的生產設施,還在一些頂級終端用戶的勘探開發業務附近設有精加工設施,其中包括其最大客戶沙特阿美(Saudi Aramco)所在的沙特阿拉伯。7月24日,OMSE公佈了截至2025年3月31日的全年業績。年內,公司營收達約2.04億美元,經營利潤約6,000萬美元,均同比大幅增長。此外,公司現金充裕,截至2025年3月31日,在手現金達7,580萬美元。值得留意的是,OMSE的2025財年的經營利潤同比增長強勁。公司因於2023年前進行了重組,管理層從大股東手中進行buyout併購,故在2024年按國際會計標準計價,把資産淨值溢價約4940萬美元計入,形成2023/2024年財年的淨利潤高達8,000萬+美元。扣除相關一次性資産溢價計入後,2025財年的經營利潤達到5990萬美元,較2024財年的4340萬美元實現同比大幅增長。特阿美訂單長達10年 收益穩健根據Roth Capital 的預測,OMSE未來幾年的增長將維持於一個高水平。主要受益於公司在西非安哥拉和泰國市場獲得了新訂單,在拓展全球業務方面取得重大進展。而更大的動力是來自於2024 年初,OMSE 與全球最大的石油能源公司沙特阿美 (TADAWUL: 2222) 簽署了為期 10 年的供應協議,每年可能產生 1.2 億至 2 億美元的收益。未來,大有機會通過併購進一步擴大其業務覆蓋面或市佔率,持續提升盈利能力。公司已投資 110 萬美元用於研發用於高壓高溫閘閥的金屬密封件,並已完成工程第一階段。料未來將成新增收入來源。綜上可見,公司基本面強勁,加上佔全球2023年石化能源需求超過15.6%的美國重返傳統能源年代,不僅有望拉動供需平衡、支持國際油價,還有望推動包括頁岩油的原油產量的上升,利好一眾與油價關連度較少的油服基建股,如OMSE。最後,美國力圖通過擴大傳統能源交易鞏固美元在國際結算系統的霸主地位,這必然是一個長期趨勢。高盛預期2025年布蘭特原油價格有望維持於每桶76美元,亦進一步反映了這個潛在的美國力量。無論從短期或中長期來看,油服基建股的投資價值正在穩步提升。根據彭博數據,全球油服及相關油田裝備行業的平均市場率為15倍,而OMSE的現價市盈率僅為5倍,反映估值大幅落後。值得一提的是,公司在手現金充足,加上業務穩健,不排除日後派息,值得加倍關注。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More

百仕達(1168)擬更名「Z Fin Limited」控股股東換股以行動彰顯信心和支持 轉型戰略升級前景看俏

香港,2025年7月25日 - (亞太商訊 via SeaPRwire.com) - 百仕達控股有限公司(1168)於前天(7月23日)發佈公告,建議將公司名稱更改為「Z Fin Limited」,正式宣告其戰略的全面升級。緊隨其後,公司確認已收到控股股東的正式通知,將行使其全部可換股債券。這兩項行動接連發生,正是代表控股股東在得知建議更名後,對公司的未來發展方向看得更為清晰。市場現已瞭解到,這並非一次從零開始的轉型,而是一次基於已有豐碩成果的戰略昇華,其未來發展藍圖亦已相當明確。深厚佈局浮現,品牌戰略確立與市場普遍認知不同,百仕達並非今日才踏足金融科技。事實上,集團近年早已洞悉行業潛力,並已積極完成多項重量級的戰略佈局。其投資組合中,包括了知名的眾安在綫(6060.HK),以及其合營公司ZA Global。而ZA Global全資擁有的眾安銀行(ZA Bank),不僅是香港規模最大的數字銀行,更是首間為穩定幣發行人提供專屬儲備銀行服務的銀行,足證其在Web3領域的領先地位。此外,集團的投資版圖亦已觸及金管局穩定幣發行人「沙盒」的參與者圓幣科技(RD Technologies)。公司的未來藍圖相當清晰:以現有穩健的地產業務為基礎,結合潛力巨大的金融科技業務,形成「雙線發展」的增長模式。為順應香港政府積極推動數字資產中心的趨勢,集團將繼續探索包括加密資產、現實世界資產(RWA)、Web3及穩定幣等前沿領域的機遇。因此,此次更名為「Z Fin Limited」,目的極為明確,即是為了更精準地反映集團已具備的金融科技實力,及未來專注於數字資產應用場景的戰略定位。增長引擎啟動,價值期待爆發市場對百仕達的估值,顯然仍未充分反映其金融科技引擎的真實潛力,尤其是其核心資產正在發生的質變。最顯著的例子,便是其合營公司ZA Global旗下的ZA Bank。該行的經營效益正顯著改善,淨虧損率已從2023年的111%大幅收窄至2024年的42%。這組數據的背後,是一個關鍵信號:ZA Bank的業務模式已趨向成熟,正從前期投入階段,邁向健康的、可持續的增長軌道。一旦這部增長引擎正式由虧轉盈,其價值將不再是線性增長,市場期待的是一次爆發性的價值釋放。憑藉ZA Global在金融科技領域的深厚基礎,加上百仕達將來在金融科技上的投入,勢將為百仕達的帶來更為強勁的增長動力。大股東換股:看準增長潛力,彰顯對前景的信心正是看準了此等爆發性的增長潛力,控股股東近期的換股行動,其背後邏輯便不言而喻。其換股決定,不僅是其個人遠見的體現,更為全體股東及投資者帶來了實質利益:- 優化財務,為金融科技業務添注燃料: 換股直接為公司減債2億港元,極大優化了資產負債表,並消除了未來償還本金的現金流壓力。這筆資金將成為金融科技業務最直接的燃料,支持公司在新領域的探索和投資。- 鞏固股權,期待長期回報並非短期套現: 換股後,控股股東的持股比例由51.34%大幅提升至64.46%。此刻增持,顯然是看好旗下核心資產的價值即將迎來釋放,期待更豐厚的回報顯現。有個別猜測大股東會在短期內出售股份,這想法在商業邏輯上並不合理。作為持股逾六成的控股股東,若在市場上拋售股份,必然會對股價構成沉重沽壓,最終只會損害其自身原來持有的、更龐大的股份價值。因此,最符合其自身利益的選擇,必然是支持公司做大做強,透過企業內在價值的提升,來實現長遠豐厚回報。總括而言,百仕達(1168)的這次更名,是一次基於深厚實力的價值宣告。公司已清晰展示其「金融科技+地產」的雙線發展增長藍圖,而控股股東的換股行動,則是對這一藍圖最堅定的信任票。當公司的真正價值被市場重新認識,其估值重估之路或已全面開啟。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
億勝生物多劑量地誇磷索鈉滴眼液獲中國國家藥品監督管理局批准上市 ACN Newswire

億勝生物多劑量地誇磷索鈉滴眼液獲中國國家藥品監督管理局批准上市

香港,2025年7月25日 - (亞太商訊 via SeaPRwire.com) - 億勝生物科技有限公司(「億勝生物」或「集團」,股票代碼:1061.HK)欣然宣布,集團間接全資附屬公司珠海億勝生物製藥有限公司已收到國家藥品監督管理局批准於中華人民共和國進行多劑量地誇磷索鈉滴眼液(「獲批准産品」)注册及商業化。獲批准産品是一款含有3%地誇磷索鈉(5ml:150mg)的多劑量滴眼液劑型,適用於包括結膜上皮損傷和泪液异常在內的乾眼症的治療。該活性藥物成分地誇磷索鈉是一種P2Y2受體激動劑,它作用於結膜組織,促進含有水分和分泌性粘蛋白的泪液分泌。它還可促進角膜上皮上膜結合型粘蛋白的表達。通過提升泪液中的脂質含量,它從數量和質量上改善泪液异常,並顯示出使眼表狀况接近正常、改善乾眼症狀和角膜上皮損傷的療效。獲批准産品將與集團已獲批的不含防腐劑單劑量地誇磷索鈉滴眼液一並,為不同類型的中國患者提供更多優質治療選擇。此地誇磷索鈉滴眼液的成功獲批將進一步豐富集團眼科産品組合,增强集團在眼科領域的市場地位。關於億勝生物(股票代碼﹕1061.HK)億勝生物是一間專注於研發、生産和銷售基因工程藥物b-bFGF的生物製藥企業,擁有包括貝複舒®、貝複濟®、貝複新®在內的六種基因工程藥物在中國上市銷售。此外,公司還擁有包含一系列不含防腐劑單劑量滴眼液和適麗順®卵磷脂絡合碘膠囊等的多元化産品組合,主要應用於眼科及皮膚科處方藥領域的創傷修復及疾病治療。這些産品在公司於中國的44個區域辦事處的支持下,在逾14,000家醫院進行營銷和銷售。依托自身在生長因子和抗體技術領域的研發平台,億勝生物在多個臨床階段擁有强大的項目管綫,涵蓋廣泛的領域和適應症。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
Theinvestmedia.com Offers Exclusive Brokerage Account Opening Offers and In-Depth Tutorials, Empowering Investors with Precise Decision-Making ACN Newswire

Theinvestmedia.com Offers Exclusive Brokerage Account Opening Offers and In-Depth Tutorials, Empowering Investors with Precise Decision-Making

HONG KONG, July 26, 2025 - (ACN Newswire via SeaPRwire.com) - As one of the leading stock brokerage account opening offers comparison and practical investment education media platform in Hong Kong and Asia, Theinvestmedia.com ( https://theinvestmedia.com ) today proudly announced the exclusive update and launch of its fully optimized "Brokerage Account Opening Offers" special section on its website. It's also releasing a series of "Brokerage Account Opening and Platform Usage Practical Tutorials" personally written by its senior expert team. This initiative aims to empower a wide range of individual investors, especially those seeking the best brokerage account opening offers and practical platform usage tutorials, by providing timely, specific, and highly reliable information, ensuring they can make the smartest and most efficient decisions in the ever-changing global financial markets.Theinvestmedia.com's core team comprises seasoned investment bankers, securities firm management, and Certified Public Accountants (CPAs), boasting over eight years of hands-on financial investment experience. The team deeply understands the critical impact of financial information's professionalism and timeliness on investment decisions. This in-depth update focusing on brokerage account opening tutorials and exclusive offers is a testament to the team's commitment to transforming rich experience into tangible user value.Exclusive Brokerage Account Opening Offers: Real-World Testing and In-Depth Tutorial AnalysisIn response to the market's strong interest in brokerage account opening offers, Theinvestmedia.com not only provides a detailed list of all publicly available offers but also exclusively reveals account opening promotions launched in collaboration with various licensed financial brokerage partners (for details, please refer to Theinvestmedia.com's official website). These offers are not only highly attractive, but the team also provides an in-depth analysis in the tutorials, covering the application process, terms and conditions, and how to maximize the value of these account opening offers. This aims to help users clearly understand the benefits and avoid any potential confusion. The team's goal is to ensure users receive the most transparent and comprehensive information when choosing to open accounts with top-tier brokers (e.g., IBKR account opening offers, Futu, Tiger, OSL, etc.).Practical Guides: From Illustrated Brokerage Account Opening Procedures to Advanced Platform Usage Tutorials and StrategiesBeyond the brokerage account opening offers comparison, another major highlight of this update is a series of brokerage account opening and platform usage practical tutorials, thoroughly tested and verified by the team. These in-depth tutorials cover:Most Detailed Illustrated Account Opening Procedures and Techniques: Providing illustrated steps and tips for common account opening queries and operational challenges (e.g., illustrated IBKR account opening procedures).In-Depth Navigation of Different Securities Platform Functions: Introducing the trading interfaces and frequently used features for diverse investment products (e.g., US stocks, Hong Kong stocks, Japanese stocks, forex, bonds, ETFs, etc.) available on these platforms.Foreign Exchange Rate Comparisons : Offering practical advice on foreign exchange rate comparisons for USD to HKD, Yen to HKD, GBP to HKD, EUR to HKD, CAD to HKD, AUD to HKD, RMB to HKD, SGD to HKD, and other foreign currencies, as well as guidance on deposits and withdrawals in various currencies.Specific Trading Tools and Strategy Application: Sharing how the senior team leverages brokerage platforms for effective risk management and strategy execution for wealth management purpose.Every guide undergoes meticulous data collection from multiple sources, citing only authoritative data from official reports of licensed brokers and multiple account opening tests. Before publication, all content undergoes rigorous multi-team internal verification and professional review by senior compliance advisors, ensuring the authority and 100% accuracy of the information.Building Trust with a Customer-Centric Approach: User Feedback and Customer Service SupportTheinvestmedia.com is committed to being user-centric, with its trustworthiness built on transparency and prompt responsiveness. The platform has a growing number of email subscribers, whose active engagement and positive feedback widely confirm the practical value of the website's content. Theinvestmedia.com also maintains a professional customer service team, accessible via the website or email (hello@theinvestmedia.com), providing personalized assistance. This ensures that users with any questions regarding brokerage account opening offers, platform usage guides, or other tutorial-related information can receive immediate and professional support during business hours.The platform's founding team stated: "We firmly believe that truly valuable financial information must be practical, timely, and verifiable. This exclusive update on brokerage account opening offers and practical tutorials is our latest achievement in upholding this philosophy. We don't just provide 'fish'; we strive to teach 'fishing,' empowering every investor to confidently navigate the global financial markets."Theinvestmedia.com sincerely invites all readers interested in brokerage account opening offers, securities platform operations, and professional investment knowledge to visit Theinvestmedia.com immediately. Explore these exclusive resources, forged from the experience of financial experts, and embark on your journey of confident investment learning.About Theinvestmedia.comTheinvestmedia.com is an online media platform dedicated to providing individual investors with brokerage account opening offer comparisons and professional investment education. It is operated by an expert team with over eight years of hands-on financial investment experience. The website's content covers diverse investment topics, including US stocks, Hong Kong stocks, Japanese stocks, forex, bonds, and ETFs, with a particular focus on account opening offer comparisons, account opening tutorials, and stock account operations (e.g., IB account opening offers), offering in-depth analysis and explanations. Theinvestmedia.com aims to simplify complex financial concepts, helping investors build a solid foundation of investment knowledge and make informed financial decisions. All content is for actual experience sharing and public educational purposes; the platform does not provide any investment advice.Media & Reader Inquiries:Theinvestmedia.com Public Relations DepartmentEmail: hello@theinvestmedia.comWebsite: https://theinvestmedia.comFacebook: https://www.facebook.com/theinvestmediaX.com: https://x.com/theinvestmediaSOURCE: Theinvestmedia Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Ultraman Omega joins the battlefield alongside beloved Ultraman Arc in Tsuburaya Production’s new Starter Deck 03 ‘Ω to the Future’ and Booster Pack 4 ‘Gleam of Eternal Hope’ ACN Newswire

Ultraman Omega joins the battlefield alongside beloved Ultraman Arc in Tsuburaya Production’s new Starter Deck 03 ‘Ω to the Future’ and Booster Pack 4 ‘Gleam of Eternal Hope’

Starter Deck 03 ‘Ω to the Future’ marks the highly anticipated debut of Ultraman Omega in card form, featuring exclusive cards and brand new strategies that bring the latest TV series to life and allowing fans to experience the title hero’s journey.Booster Pack 04 ‘Gleam of Eternal Hope’ introduces powerful new versions of iconic Ultra Heroes including Ultraman Dyna, Z, and Trigger. These upgraded cards unlock expanded tactical possibilities, reshaping the game and delivering fresh competitive angles for seasoned players.With the release of both new sets as well as the return of fan-favourite ExP (Extra Parallel) rarity cards, and momentum building toward the Ultra League World Championship 2026, the Ultraman Card Game is poised to grow its global fanbase and strengthen its presence within the trading card game community.KUALA LUMPUR, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Tsuburaya Productions unveils today the latest additions to the ever-popular Ultraman Card Game - Starter Deck 03 ‘Ω to the Future’ and Booster Pack 04 ‘Gleam of Eternal Hope’, launching globally on Friday, 25 July 2025 and Friday, 1 August 2025 respectively. These upcoming game sets build on the momentum of the newly launched Ultraman Omega television series, as well as beloved characters such as Ultraman Arc, whilst introducing brand-new gameplay mechanics, evolution strategies and dynamic synergies centred around these iconic Ultra Heroes. Ultraman Omega Makes His First-Ever Card Game AppearanceA highlight of the new Starter Deck 03 ‘Ω to the Future’ is the much-anticipated debut of Ultraman Omega in card form. This new deck draws inspiration from the ongoing Ultraman Omega television series, which premiered in Japan earlier this month.Reflecting the show’s narrative, the deck features exclusive cards from the Ultraman Omega series, including the titular Ultraman Omega, Meteokaiju, and fan-favourite Giants of Light such as Ultraman Arc. These new cards introduce fresh gameplay mechanics that reward strategic thinking and foresight, from granting power boosts when fielding characters of the same type to enabling tactical card rotations that encourage smarter deck management. With these new mechanics and play styles, players can look forward to reliving key story moments and experiencing Ultraman Omega’s growth firsthand.As an added early-release bonus, players will also be able to receive a bonus pack of Booster Pack 04 ‘Gleam of Eternal Hope’ for every purchase of Starter Deck 03 ‘Ω to the Future’, offering fans an early taste of the upcoming expansion and even more ways to power up their decks.Fan-Favourite Heroes Return with Upgraded PowersBooster Pack 04 ‘Gleam of Eternal Hope’ continues to expand the strategic possibilities of the game, featuring powerful upgraded cards for popular Ultra Heroes including Ultraman Dyna, Ultraman Z, and Ultraman Trigger.These upgrades introduce new abilities that not only refresh existing decks but also deepen tactical options across competitive formats. With a more extensive card pool, players can look forward to more creative deckbuilding strategies that are sure to influence the current approach to gameplay.Collectors Rejoice: ExP (Extra Parallel) Cards Make a ReturnBack by popular demand, the ExP (Extra Parallel) rarity cards - first introduced in Booster Pack 02 ‘Vortex of Crimson and Azure’ - make a dazzling return in ‘Gleam of Eternal Hope’.These collector-favourite cards are known for their exclusive full-art illustrations, premium foil finish, and elegant gold framing. Scheduled to be revealed on Friday, 1 August 2025, ‘Gleam of Eternal Hope’ will see the addition of two brand-new types of ExP card, offering high visual appeal and collectability for long-time fans and new enthusiasts alike.Exclusive Box Topper: Alien Baltan The Space NinjaAdding to the excitement, each 24-pack box of ‘Gleam of Eternal Hope’ will include a special box topper card featuring Alien Baltan, one of the most iconic villains in Ultraman history.This unique card mirrors Baltan’s illusory powers, allowing an unlimited number of copies to be included in a single deck - a rare and rule-breaking mechanic. The artwork captures the classic scene of Baltan duplicating itself and unleashing its signature red freezing ray, leveraging nostalgia for long-term fans.Fans in Malaysia can look forward to purchasing the English-language Starter Deck 03 ‘Ω to the Future’ at MYR 46.00 and Booster Pack 04 ‘Gleam of Eternal Hope’ in either individual packs at MYR 18.00 or as a 24-pack box at MYR 432.00 at authorised hobby stores, major retailers, and online platforms.These releases are poised to equip both new and veteran Ultra Leaguers with competitive decks ahead of major events, including the upcoming inaugural Ultra League World Championship 2026, set to take place on 9 and 10 May 2026 in Tokyo, Japan. This prestigious tournament will see players from around the world battling through regional qualifiers for a shot at the title of world’s best Ultra Leaguer, with exclusive cards and gameplay accessories up for grabs. For more information on the Ultraman Card Game, please refer to https://ultraman-cardgame.com/page/my/top.About Tsuburaya ProductionsTsuburaya Productions is a global entertainment company providing content, products and services full of creativity and innovation. Since the airing of Ultra Q and Ultraman in 1966, the company has continued to create characters and stories that are loved by fans worldwide.TSUBURAYA PRODUCTIONS Official Global Site: https://tsuburaya-prod.com/Ultraman Card Game Official Website: https://ultraman-cardgame.com/About Ultraman Card GameThe Ultraman Card Game is a dynamic trading card game developed by Tsuburaya Productions, bringing the iconic Ultraman universe to life through strategic gameplay and collectible cards. Designed for fans of all ages, the game features high-quality artwork showcasing Ultraman's heroes, kaiju, and special moves, offering both engaging play and collectibility. With simultaneous releases in multiple languages across various regions, the Ultraman Card Game invites players around the world to explore the rich legacy of Ultraman, engage in epic battles, and grow their collections. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China ACN Newswire

Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China

HONG KONG, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” or the “Group”, Stock Code: 1061.HK) is pleased to announce that (Zhuhai Essex Bio-Pharmaceutical Company Limited), an indirect wholly-owned subsidiary, has received approval from (National Medical Products Administration) for the registration and commercialisation of the multi-dose Diquafosol Sodium Eye Drops in the PRC.The Approved Product is a multi-dose eye drop formulation containing 3% diquafosol sodium (5ml:150mg), indicated for the treatment of dry eye syndromes such as conjunctival epithelium injury and tear abnormalities. The active pharmaceutical ingredient, diquafosol sodium, is a P2Y2 receptor agonist that acts on conjunctival tissues to promote the secretion of tears containing water and secretory mucins. It may also promote the expression of membrane-bound mucins on corneal epithelium. Boosting the lipid content in tears, it should quantitatively and qualitatively improve tear abnormalities and demonstrate efficacy in bringing the ocular surface condition closer to normal, and improve symptoms of dry eye and corneal epithelial damage.The Approved Product, together with the previously approved preservative-free unit-dose Diquafosol Sodium Eye Drops collectively, collectively provide more high-quality treatment options for patients in the PRC. The approval will further enrich the Group’s ophthalmic product portfolio and strengthen its market position in ophthalmology segment.About Essex (Stock Code:1061.HK)Essex is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology.These products are marketed and sold through approximately 14,000 hospitals, supported by the Company’s 44 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, Essex maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million ACN Newswire

Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million

SHANGHAI, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the “Sellers”), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue.Everest Medicines, together with its controlling shareholder CBC Group and the placing agents, entered into a placing and subscription agreement for the sale of 22,561,000 shares at a purchase price of HK$69.70 per share, representing:- a discount of approximately 10.12% to the closing price of HK$77.55 per share on July 24, 2025.- a discount of approximately 4.98% to the average closing price of HK$73.35 per Share as quoted on the Stock Exchange for the five consecutive trading days immediately prior to and including the Last Trading Date.- a premium of 16.15% to the volume weighted average price of HK$60.01 per Share as quoted on the Stock Exchange for the thirty consecutive trading days immediately prior to the Last Trading Date and including the Last Trading Date.The gross proceeds from the Placing and Subscription are expected to be approximately HK$1,572.50 million, and the net proceeds (after deducting all related expenses, including commission and levies) will be approximately HK$1,553.39 million.Everest Medicines intends to use approximately 50% of the net proceeds (approximately HK$776.69 million) to support global research and development of pipeline products, approximately 40% (approximately HK$621.36 million) to commercialization efforts including the launch of new products, and 10% (approximately HK$155.34 million) to working capital and general corporate purposes.“This placement was well-received by several leading international long-only funds and was significantly oversubscribed, reflecting strong capital market confidence in Everest’s commercial execution capabilities and innovative R&D strengths,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “It also underscores investors’ endorsement of our long-term strategic vision. We will use the proceeds to accelerate the development of innovative pipelines and our proprietary AI+mRNA platform, while advancing the commercialization of our existing portfolio. With a strengthened capital base, we are poised to drive both commercialization and innovation, delivering greater value to patients and shareholders.”Everest has built an industry-leading, fully integrated, and localized AI+mRNA platform, enabling the development of multiple oncology and autoimmune disease programs, including EVM14, an off-the-shelf therapeutic mRNA cancer vaccine; EVM16, a personalized mRNA cancer vaccine; and an in vivo CAR-T program aimed at building a differentiated portfolio of precision immunotherapies.- The first patient has been dosed with Everest’s internally developed personalized mRNA cancer vaccine (PCV) EVM16 at Peking University Cancer Hospital in the investigator-initiated clinical trial (IIT). Early results showed strong immunogenicity and specific T-cell responses even at a low starting dose in advanced cancer patients.- The Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) vaccine, has been accepted by both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA), making it Everest's first mRNA cancer therapeutic vaccine to achieve dual IND submissions in both China and the United States. The first clinical batch of EVM14 was successfully released from Everest’s Jiashan manufacturing site on June 9, and is anticipated to be delivered to U.S. clinical centers by mid-August. This batch will support the clinical trials of EVM14 in both China and the United States (US).- Everest’s in vivo CAR-T program is founded upon its proprietary targeted LNP (tLNP) delivery system and has shown promising results in both humanized mouse models and non-human primates. It offers key advantages including off-the-shelf availability, lymphodepletion-free administration, and dose controllability.EVER001, a next-generation covalent reversible BTK inhibitor with global rights, is advancing through global multi-center clinical studies for glomerular diseases such as primary membranous nephropathy (pMN). Positive results from its Phase 1b/2a clinical trial demonstrated rapid onset, durable response, good tolerability, and oral convenience, offering strong potential to address unmet needs in renal disease treatment worldwide.NEFECON®, the first and only etiological treatment for IgA nephropathy (IgAN) full approved in China, the U.S., and Europe, continues to gain strong commercial traction in China following its inclusion in the National Reimbursement Drug List (NRDL), benefiting over 20,000 patients to date. Everest is also accelerating the development of its proprietary diagnostic test for Gd-IgA1 to build an integrated disease management ecosystem encompassing diagnosis, treatment, and long-term care.The New Drug Application (NDA) for Etrasimod (VELSIPITY®) has been accepted in Mainland China, with approval anticipated between late 2025 and early 2026. The NDA has also been accepted in South Korea. VELSIPITY® has been commercially launched in Macao SAR, Singapore and Hong Kong SAR in 2024. As Everest’s third commercialized product, VELSIPITY® has been officially approved by the Guangdong Provincial Medical Products Administration for adult patients with moderately to severely active UC. It is now available at medical institutions designated under the Connect Policy in the Greater Bay Area. In March 2025, Everest has launched the construction project at its Jiashan manufacturing site to support the local production for VELSIPITY®.Everest Medicines is accelerating the strategic advancement of its core pipeline and AI+mRNA technology platforms to further solidify its position as a leading innovative biopharmaceutical company in Asia.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
雲頂新耀宣布配售股份 擬集資約15.725億港元 ACN Newswire

雲頂新耀宣布配售股份 擬集資約15.725億港元

上海,2025年7月25日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀有限公司(HKEX1952.HK)是一家專注於創新藥研發、臨床開發、制造和商業化的生物制藥公司,今日宣布以先舊後新配售22,561,000股,集資約15.725億港元,發行股份數占現有股本約6.87%, 占經擴大後的總股數約6.43%。雲頂新耀、賣方(控股股東康橋資本)與配售代理簽訂先舊後新方式的配股協議,配售22,561,000股份,每股配售價69.70港元,較於最後交易日(即配售及認購協議日期前一天)在聯交所報所報收市價每股77.55港元折讓約10.12%,亦較於緊接最後交易日(包括該日)前連續五個交易日在聯交所所報平均收市價每股73.35港元折讓約4.98%,較於緊接最後交易日(包括該日)前連續三十個交易日在聯交所所報成交量加權平均價每股60.01港元溢價16.15 %。所得款項總額預期約為15.725億港元,而所得款項淨額(經扣除所有相關成本及開支,包括傭金及征費)將約為15.534億港元。雲頂新耀預計配售所得款項,其中50 %(約7.767億港元)用於開發自主全球研發平台及新產品管線;另外40 %(約6.214億港元)用於推進新產品商業化,包括推出新產品;及10 %(約1.553億港元)用作營業資金以及一般及行政用途。雲頂新耀首席執行官羅永慶表示,「此次配售受到多家國際長線持有基金青睞,獲得數倍超額認購,反映了資本市場對雲頂新耀商業化能力與創新研發實力的高度認可,也體現出投資者對公司長期發展戰略的充分信心。我們將充分利用此次融資所得,加快創新藥物和AI+mRNA平台的開發,同時推進現有產品的商業化進程。憑借更為充足的資本基礎,我們有信心在商業化拓展與研發創新雙線並進,不斷為患者與投資者創造更大價值。」公司已構建國際領先的、完全整合且本地化的AI+mRNA平台,重點推進腫瘤和自身免疫疾病領域的產品管線開發,包括通用型現貨腫瘤治療性疫苗EVM14、個體化腫瘤治療性疫苗EVM16,以及自體生成CAR-T項目。- 雲頂新耀自主研發的首款個性化mRNA治療性腫瘤疫苗EVM16 的IIT研究已在今年3月於北京大學腫瘤醫院順利完成首例患者給藥。該臨床試驗初步數據顯示,即使低起始劑量也能激發晚期腫瘤患者特異性T細胞反應,具有良好的免疫原性。- 通用型現貨腫瘤治療性疫苗EVM14注射液的新藥臨床試驗申請(IND)已獲中國國家藥品監督管理局和美國食品藥品監督管理局(FDA)受理,成為公司首個實現「中美雙報」的mRNA腫瘤治療性疫苗。雲頂新耀嘉善工廠已於2025年6月9日順利放行首批GMP臨床試驗樣品,該批樣品將用於支持雲頂新耀在中美兩地開展EVM14的臨床試驗。- 自體生成CAR-T項目也已在人源化小鼠與非人靈長類(猴)模型中驗證有效,具備現貨型、無需淋巴耗竭、劑量可控等優勢,展現了開發用於腫瘤及自身免疫疾病的潛力。擁有全球權益的新一代共價可逆BTK抑制劑EVER001正開展全球多中心臨床研究,主要用於治療原發性膜性腎病(pMN)等多種原發性腎小球疾病。其在原發性膜性腎病1b/2a期研究中展現出起效快、緩解持續、耐受性好、口服便捷等綜合優勢,有望為全球患者帶來更優治療選擇。耐賦康®作為首個且唯一在中國、美國和歐洲獲得完全批准的IgA腎病對因治療藥物,自納入中國國家醫保目錄以來快速放量,已惠及超過兩萬名患者。公司亦正加快推進Gd-IgA1診斷試劑的轉化,致力打造覆蓋診斷、治療、長期管理的一體化IgA腎病疾病管理生態。伊曲莫德(維適平®)在中國大陸的新藥上市申請也已獲受理,預計2025年底至2026年初獲批,其新藥上市申請也已獲韓國受理。伊曲莫德已相繼在中國澳門,新加坡和中國香港獲批,並被納入粵港澳大灣區內地9市臨床急需進口港澳藥品醫療器械目錄(2024年),已在大灣區先行使用惠及潰瘍性結腸炎患者,成為雲頂新耀第三款商業化新藥。2025年3月,雲頂新耀啟動了伊曲莫德位於嘉善工廠的生產建設項目,為伊曲莫德的本地化生產提供支持。雲頂新耀正加快推進多個核心管線及技術平台的戰略布局,進一步鞏固其在亞洲領先創新藥企中的市場地位。關於雲頂新耀雲頂新耀是一家專注於創新藥和疫苗研發、臨床開發、制造和商業化的生物制藥公司,致力於滿足亞洲市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先制藥企業從事過高質量研發、臨床開發、藥政事務、化學制造與控制(CMC)、業務發展和商業化運營,擁有深厚的專長和豐富的經驗。雲頂新耀已打造多款疾病首創或者同類最佳的藥物組合,公司的治療領域包括腎科疾病、感染性和傳染性疾病、自身免疫性疾病。有關更多信息,請訪問公司網站:www.everestmedicines.com。前瞻性聲明本新聞稿所發布的信息中可能會包含某些前瞻性表述,乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期,可能會使用"將"、"預期"、"預測"、"期望"、"打算"、"計劃"、"相信"、"預估"、"確信"及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證,會受到風險、不確定性及其他因素的影響,有些乃超出本公司的控制範圍,難以預計。因此,受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響,實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發布日後最新信息、未來項目或情形的任何義務,除非法律要求。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
鎂信健康攜手多方力量 共促粵港澳大灣區醫療保險發展 ACN Newswire

鎂信健康攜手多方力量 共促粵港澳大灣區醫療保險發展

香港,2025年7月25日 - (亞太商訊 via SeaPRwire.com) - 隨著粵港澳大灣區建設不斷深化,區域內居民對跨境醫療服務與醫療保險協同發展的需求日益迫切。7月24日,一場以"粵港澳大灣區醫療保險發展"為主題的行業論壇於香港舉行,來自保險、醫療、科技等領域的機構代表與專家齊聚一堂,圍繞跨境醫療保障一體化、保險產品創新與服務標準化等核心議題展開深入交流。論壇期間,各方共同探討大灣區醫療保險發展新路徑,並見證跨境醫療行業解決方案正式發佈。聚焦醫療互聯互通,發佈跨境保障方案論壇上,鎂信健康創始人兼首席執行官張小棟先生指出,粵港澳大灣區作為我國經濟最具活力的區域之一,在國家發展大局中具有重要戰略地位。"塑造健康灣區"戰略的踐行,是對千萬灣區居民"病有所醫、醫有所保"期盼的回應。鎂信健康圍繞"藥品可及、醫療連接、支付簡化"三個核心痛點,推出跨境醫療解決方案,具體涵蓋:第一件事,是"把藥帶進來"。依託鎂信創新藥械的資源優勢,致力於把最新上市的癌症、罕見病治療藥、以及海南特藥特械等全球創新藥械帶到大灣區患者的身邊;第二件事,是"把醫連起來"。提供包括專家預約、陪診、第二診療意見、住院手術安排等全流程服務,優化港人北上診療體驗;第三件事,是"把支付變簡單"。依託鎂信的一碼直付平臺,探索實現患者北上就醫無需墊付,努力讓跨境醫療的保險理賠像掃碼一樣簡單。鎂信健康創始人兼首席執行官 張小棟在跨境醫療解決方案環節,中再壽險產品開發部總經理王明彥先生與鎂信健康首席商務官郎立良先生也分別發表主題演講。他們深入探討了跨境醫療在大灣區面臨的機遇與挑戰,分享了在產品設計、服務模式等方面的創新實踐與經驗。匯聚行業智慧 共建健康灣區活動現場同步舉行「服務國家戰略,共建健康灣區」發佈儀式,宣佈各方將在資源整合,模式創新等層面持續合作,探索更多適配於大灣區的醫療保險產品與服務。在隨後的圓桌論壇環節,由鎂信健康首席商務官郎立良先生擔任主持人,與尚志醫療集團醫務行政總監、外科專科醫生郭寶賢先生,中國太平洋人壽(香港)聯席行政總裁、香港精算學會(ASHK)前主席、現任理事Simon Lam先生,香港精算視覺保險學會會長、大灣區保險學院聯合創始人牟劍群先生,以及諾華香港的相關代表深入探討大灣區醫療保融合的各方實踐。各位嘉賓從不同角度分享了對大灣區醫療保險發展的見解與建議,探討了如何加強大灣區醫療保障合作、提升醫療服務水準、促進保險產品創新等關鍵問題。鎂信健康在論壇中積極發聲,提出通過公立+特需/私立結合、資源整合等方式,賦能醫療資源的互補和互通,推動大灣區醫療保險服務的升級與優化,為大灣區居民提供更加優質的醫療保障體驗,得到了與會嘉賓的廣泛認可與支持。「服務國家戰略,共建健康灣區」發佈儀式凝聚信心 攜手同行論壇壓軸環節,中國太平洋人壽保險原董事長、大家保險集團原總經理徐敬惠先生發表主旨發言。他從行業發展的宏觀角度,對大灣區醫療保險的未來發展進行了深入分析與展望,總結出三個"心"的感受。首先是信心,近年來,在各項政策的推動下,大灣區醫療互聯互通成效明顯,多項跨境醫療福利成功"過河",跨境醫療的"民生流量"也在政策協同的推動下持續升溫,這讓我們對未來充滿信心。第二個是"初心",徐敬惠先生強調,"以人民健康為中心"的初心,是破解難題的指南針。最後是"同心",不管是中再、鎂信,還是醫療、醫藥機構,都在各自領域搭建著連通橋,各方攜手共同推動大灣區醫療保險事業的發展,為大灣區居民的健康保駕護航。此次論壇發佈的"灣區跨境醫療解決方案",鎂信健康深度參與並提供特藥支持。它打破了地域壁壘,整合了兩地資源,為跨境醫療服務的標準化、一體化樹立了典範。這種合作模式不僅提升了居民的健康保障體驗,也為行業探索出了一條可持續發展的新路。本次粵港澳大灣區醫療保險發展論壇的順利舉行,不僅推動了灣區保險行業對跨境醫療議題的深度關注,也為後續創新與產業協作奠定了良好基礎。鎂信健康作爲參與方之一,將持續深耕大灣區,攜手更多夥伴推進醫療保障數智化轉型,助力實現健康灣區的美好願景。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
International Land Alliance Announces Tiny Home Offerings at Cabo Oasis Development ACN Newswire

International Land Alliance Announces Tiny Home Offerings at Cabo Oasis Development

SAN DIEGO, July 24, 2025 - (ACN Newswire via SeaPRwire.com) - International Land Alliance, Inc. (OTCQB: ILAL) (“ILAL” or the “Company”), a global real estate investment and development firm, today announced the launch of a new product offering at its flagship Cabo Oasis and Valle Divino developments in Baja California. With a focus on sustainable design and affordability, this initiative marks a significant expansion of the Company’s master-planned communities.International Land Alliance has identified initial locations within its 500-acre Cabo Oasis beachfront development to introduce Tesla-powered tiny homes. These units are designed to serve as vacation, second, or retirement residences—offered at a purchase price of under $100,000 or a lease option for under $1,000 per month.“We are bringing sustainable, high-quality living to everyone at a price that was once unimaginable,” said Frank Ingrande, President & CEO. “These homes emphasize eco-friendly design, compact efficiency, and cutting-edge technology, all while helping solve the affordability crisis that’s impacting many, especially in California.”As part of our broader vision to expand Cabo Oasis, ILAL is developing separate private neighborhoods within the master-planned community to accommodate a wide variety of homeownership needs and budgets—including condominiums, private estates, and these new tiny home options.The Company is currently in discussions with a leading tiny home manufacturer and expects to receive its first Tesla-powered model at Cabo Oasis within the next 30 days. The name of the provider will be announced shortly thereafter.The tiny homes will be available in both stationary and mobile versions, enabling owners to relocate between ILAL’s growing portfolio of communities across Baja California.Key Features of the Cabo Oasis Tiny Homes:Solar-Powered Everything – Integrated Tesla Solar Roof panels and a Powerwall battery ensure energy independence making this 100% off-grid capable.Smart Home Integration – Includes full home automation for lighting, climate, and security controls.Sleek, Futuristic Design – Modular interiors that maximize space and feature premium finishes.Zero Utility Costs – Energy-efficient systems designed to eliminate traditional energy bills.About Cabo OasisCabo Oasis is International Land Alliance’s flagship beachfront community in Baja California, featuring 500 acres of master-planned development with ocean views, resort amenities, and a wide range of residential options designed for sustainable coastal living.About Valle DivinoLocated in the heart of Baja’s wine country, Valle Divino is a luxury vineyard community that offers scenic living amidst Ensenada’s world-renowned wine region. The project blends boutique vineyard living with modern sustainability.About International Land Alliance, Inc.International Land Alliance, Inc. (OTCQB: ILAL) is a publicly traded real estate development company focused on acquiring desirable land and real estate assets in Northern Baja California and Southern California. With a mission to provide accessible housing solutions through innovative design and technology, ILAL builds environmentally friendly communities for vacation, retirement, and investment buyers.International Land Alliance, Inc. (OTCQB: ILAL) is an international land investment and development firm based in San Diego, California. As its’ core mission, the Company has embraced technology for sustainable and socially responsible solutions, in addition to using proptech and construction tech advanced applications to meet these goals. The Company is focused on acquiring attractive raw land primarily in Northern Baja California, often within driving distance from Southern California. The Company serves its shareholders by devoting considerable time and resources to seeking out the finest sites available and obtaining the necessary development permits to build a compelling portfolio of properties, which provide a diversity of investment and living options. Please visit: www.ila.company.For media inquiries, contact:Investor Relationsinfo@ila.company(877) 661-4811www.ila.company Safe Harbor StatementThe press release may include certain statements that are not descriptions of historical facts but are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements may include the description of our plans and objectives for future operations, assumptions underlying such plans and objectives, and other forward-looking terminology such as "may," "expects," "believes," "anticipates," "intends," "projects,” or similar terms, variations of such terms or the negative of such terms. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein. Such information is based upon various assumptions made by, and expectations of, our management that were reasonable when made but may prove to be incorrect. All such assumptions are inherently subject to significant economic and competitive uncertainties and contingencies beyond our control and upon assumptions with respect to the future business decisions which are subject to change. Accordingly, there can be no assurance that actual results will meet expectations and actual results may vary (perhaps materially) from certain of the results anticipated herein. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
HKTDC Research Report: Exploring Opportunities in Hong Kong’s Proprietary Chinese Medicine Industry ACN Newswire

HKTDC Research Report: Exploring Opportunities in Hong Kong’s Proprietary Chinese Medicine Industry

- The implementation of streamlined approval procedures for Hong Kong- and Macao-registered proprietary Chinese medicines (“pCms”) by mainland China presents significant opportunities for Hong Kong companies to expand into the Greater Bay Area and other mainland market.- A unified and comprehensive registration system strengthens the quality control of Hong Kong's pCms, reinforcing confidence among other regulatory bodies and stakeholders.- Hong Kong's first Chinese medicine hospital will gradually commence operations by year end. This will help promote the popularity of Chinese medicine and pCms.HONG KONG, July 24, 2025 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (“HKTDC”) today released a report, "Challenges and Opportunities in Hong Kong's Proprietary Chinese Medicine Industry," that analyses the sector’s development, challenges, and export potential of Hong Kong’s pCm sector. With the completion of the transitional registration process for pCms in June this year, all pCms sold in Hong Kong now hold formal registration, marking a new era in the regulatory regime. The Chinese Medicine Hospital of Hong Kong is set to begin operations by late 2025 further popularising pCms. Additionally, mainland China has streamlined approval procedures for Hong Kong-registered traditional pCms, creating easier access to the mainland market.Hong Kong’s pCms enjoy a strong reputation, with streamlined registration procedures facilitating expansion into the Mainland marketHong Kong currently has approximately 2,000 companies involved in pCms and Chinese herbal medicine-related businesses, including import/export trade, manufacturing, wholesale and retail. Among these, some 264 enterprises are listed as local pCm manufacturers. The majority of pCms produced in Hong Kong are geared toward the consumer market. In 2024, Hong Kong’s pCm exports totaled HK$2.88 billion with 93% locally produced, setting the industry apart from re-export-driven sectors. Mainland China remains the largest export market, accounting for over 70% of exports, followed by Macao (20%), and ASEAN (6%).Wing Chu, Principal Economist (Greater China) of the HKTDC, stated: "Many Hong Kong proprietary Chinese medicines companies are eager to expand exports especially to the mainland market although pCm imports in mainland China are relatively small, with different pCms registration system and technical standards from those of Hong Kong. Notably, Hong Kong’s pCms are highly regarded in Southern China and overseas Chinese communities, and streamlined approval procedures in mainland China for traditional pCms of Hong Kong and Macao offer significant opportunities for Hong Kong businesses to expand into the Greater Bay Area and other mainland markets. Additionally, the rise of online shopping enables companies to leverage cross-border e-commerce platforms to access mainland and overseas markets, provided they comply with the corresponding regulatory requirements.”Comprehensive registration system drives standardisation of Chinese medicineThe report indicates that, in recent years, the HKSAR Government has actively promoted the development of Chinese medicine. Key initiatives include the establishment of the Chinese Medicine Council of Hong Kong to oversee the registration and management of pCms, and continuous support for Chinese medicine services in areas such as education, medical treatment, and scientific research. These efforts have enabled Hong Kong to cultivate professional Chinese medicine talent and promote the modernisation of Chinese medicine. Earlier this month, some 345 Hong Kong enterprises, including traders, registered a total of 8,244 pCms.The report states that a unified and comprehensive registration system enhances the quality control of Hong Kong's pCms, further increasing the confidence of other regulatory bodies and stakeholders in these products. Hong Kong's first Chinese medicine hospital is set to open in late 2025, providing comprehensive diagnostic and treatment services with Chinese medicine, which will drive the popularisation of Chinese medicine and pCms.In addition, Hong Kong pCm companies and local universities are committed to developing new pCms to further expand the market. Recently, the Centre for Chinese Herbal Medicine Drug Development at Hong Kong Baptist University (HKBU), funded by the Innovation and Technology Commission of HKSAR Government under the InnoHK Research Clusters, developed a novel drug, CDD-2101, for the treatment of chronic constipation. The innovation is based on previous pilot clinical studies and basic research on the traditional Chinese herbal formulation "MaZiRenWan”. For the first time, it has received authorisation for clinical research in the United States.Prof. BIAN Zhaoxiang, Director of the Centre for Chinese Herbal Medicine Drug Development and Associate Vice-President (Clinical Chinese Medicine) at HKBU, said: "Our goal is to collect sufficient safety and efficacy data to obtain FDA approval for CDD-2101 as a marketable new drug and successfully launch it in the United States. This represents not only a major breakthrough in the research and development of Chinese medicine in Hong Kong but also an important step in driving the standardisation and internationalisation of Chinese medicine.”Mainland market surpasses RMB450 billionMainland China, the world's largest pCm market valued at RMB450 billion, streamlined registration and approval procedures in 2021 for traditional pCms for external use being sold in Hong Kong and Macao. In January 2025, the National Medical Products Administration further simplified the approval process for traditional pCms for oral use, provided they have been in use in Hong Kong for more than 15 years and whose production processes comply with Good Manufacturing Practice (GMP) requirements. Relevant application materials and technical requirements were also released in April this year. The report notes that the implementation of the streamlined registration procedures opens a more convenient channel for Hong Kong companies to expand into the Greater Bay Area and other mainland markets.The recognition and acceptance of pCms differ across overseas regions. In many international markets, pCms are categorised and regulated as herbal medicines, health foods or dietary supplements. However, many Southeast Asian countries have specific, similar legal requirements for pCms, providing a clear pathway to enter these markets.The rapid growth of global e-commerce has created new sales channels for Hong Kong’s pCms through cross-border e-retail. For the mainland market, the report points out that certain pCms for external use, such as Chinese medicinal wines and cooling oils, have been incorporated in the Cross-border E-commerce Retail Import Commodity List, allowing relevant products to be sold to mainland China through cross-border e-commerce channels.In overseas markets, the e-commerce retail sector in ASEAN is experiencing significant growth, fueled by robust demand for herbal and health-related products in local markets. By adhering to local regulations, Hong Kong pCm enterprises can capitalise on additional business opportunities through online channels.Annual Chinese Medicine Conference to Share Latest Research FindingsTo foster the development of the Chinese medicine industry, the International Conference of the Modernization of Chinese Medicine & Health Products will be held at the Hong Kong Convention and Exhibition Centre from 15 to 16 August 2025. The conference is jointly organised by the Modernized Chinese Medicine International Association, the HKTDC and 10 scientific research institutions. During the event, 21 scholars and experts from medical schools, research institutions, pharmaceutical companies and organisations from mainland China, Hong Kong, Malaysia and Thailand will discuss the latest research progress in the prevention and treatment of tumors, inflammation, and cardiovascular and cerebrovascular diseases using traditional medicine. They will also present a number of related clinical research results and share successful cases. For more details, please visit: https://www.hktdc.com/event/icmcm/en.Report and photo download: https://bit.ly/45kCaXuThe HKTDC today released its research report, "Challenges and Opportunities in Hong Kong's Proprietary Chinese Medicine Industry." Pictured from left are Wing Chu, Principal Economist (Greater China Research Team) at the HKTDC, and Prof. Bian Zhaoxiang, Director of the Centre for Chinese Herbal Medicine Drug Development at Hong Kong Baptist UniversityWing Chu, Principal Economist (Greater China Research Team) at the HKTDC, pointed out that mainland China has streamlined the approval procedures for eligible traditional proprietary Chinese medicines from Hong Kong and Macao, providing more opportunities for Hong Kong businesses to expand into the Greater Bay Area and mainland marketsProf. Bian Zhaoxiang, Director of the Centre for Chinese Herbal Medicine Drug Development at HKBU, stated that the university’s earlier development of a novel drug for chronic constipation is based on an ancient Chinese herbal formulation and was authorised for clinical research in the United States for the first time. This marked an important step in driving the standardisation and internationalisation of Chinese medicineMedia EnquiriesOgilvy Public RelationsChole ChanTel: (852) 6809 6633Email: chloe.chan@ogilvy.comLeanne PokTel: (852) 9379 9694Email: leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley SoTel: (852) 2584 4049Email: stanley.hp.so@hktdc.orgSerena CheungTel: (852) 2584 4272Email: serena.hm.cheung@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Quantum Solutions Announces Strategic Bitcoin Treasury Initiative ACN Newswire

Quantum Solutions Announces Strategic Bitcoin Treasury Initiative

HONG KONG, July 24, 2025 - (ACN Newswire via SeaPRwire.com) - Quantum Solutions Co.,Ltd. (2338.T), a Tokyo Stock Exchange-listed company, announced the official launch of its Bitcoin treasury initiative in 23rd July. Over the next 12 months, the company plans to gradually build a reserve position of up to 3,000 Bitcoins (BTC) as part of a broader long-term strategy to diversify its corporate treasury assets. The initiative will be managed and executed by its wholly owned Hong Kong subsidiary, GPT Pals Studio Limited, and will begin with an initial investment of USD 10 million provided by international investment firm Integrated Asset Management (Asia) Limited.This marks Quantum Solutions’ first public move into digital asset allocation. The company views Bitcoin as a long-term, strategic reserve instrument and will implement the plan in phases to ensure proper risk control and financial governance. The 3,000-BTC target will be pursued in stages, with procurement timing and scale subject to prevailing market conditions, capital availability, and regulatory context.Integrated Asset Management (Asia) is a Hong Kong-based investment company that led the acquisition of Forbes Media in 2014. The firm, founded by Tak Cheung Yam, specializes in public and private equity investments. Mr. Yam, through its controlled entities, including Integrated Asset Management (Asia), is a major shareholder of Forbes Media, with the Forbes family retaining a minority stake. Integrated Asset Management’s engagement in this initiative underscores a growing institutional openness toward incorporating Bitcoin within modern corporate treasury considerations.The operational responsibility for the Bitcoin reserve project lies with GPT Pals Studio Limited, which has begun establishing a secure and auditable digital asset infrastructure, including segregated cold and hot wallet systems, internal controls, and accounting mechanisms. The company’s board and audit committee will provide periodic oversight of the portfolio’s valuation, exposure, and governance, in accordance with applicable regulatory and accounting standards.At current market prices, the target reserve of 3,000 BTC would be equivalent to approximately JPY 53.8 billion (USD 350 million). The company clarified that this is a long-term positioning effort rather than a short-term speculative activity and that it intends to align asset deployment with financial stability and shareholder value.“We are uniquely positioned to build a Bitcoin-first capital structure. Our goal is not only to accumulate Bitcoin, but to do so with institutional-grade discipline,” said Francis Zhou, CEO of Quantum Solutions. “We are in advanced discussions with top-tier asset managers, sovereign wealth allocators, and fintech leaders to scale our treasury roadmap responsibly and rapidly.”Globally, an increasing number of public companies and institutional investors are adopting Bitcoin as a hedge against inflation and monetary policy risk. Quantum Solutions’ initiative places it among a growing group of companies taking early steps toward integrating blockchain-based assets into their financial frameworks. The decision to leverage Hong Kong as the operational base reflects confidence in the region’s infrastructure, policy clarity, and gateway role for global capital engagement.Tak Cheung Yam, founder of Integrated Asset Management Limited, shared his perspective on Quantum Solutions: "Quantum Solutions demonstrates a clear strategic vision and determination. I see compelling potential in their approach to building a significant Bitcoin treasury, and I look forward to supporting their efforts in unlocking institutional pathways and capital alignment. It's a timely opportunity for firms with global ambition and focused execution."This launch represents a significant development in Quantum Solutions’ broader capital strategy, transitioning from a traditional AI and tech solutions provider to an enterprise with a forward-looking, diversified financial architecture. The company will continue to explore ways to enhance its treasury structure by evaluating new asset classes and cross-border capital tools that strengthen its long-term balance sheet resilience.If the Bitcoin reserve program generates a material impact on the company’s financial performance in the future, disclosures will be made in accordance with Tokyo Stock Exchange regulations and financial reporting requirements.About Quantum Solutions Co., Ltd.Quantum Solutions Co., Ltd. (Tokyo Stock Exchange: 2338.T) is a Tokyo-based high-growth technology company specializing in artificial intelligence, big data analytics, and blockchain-related innovation. Founded in 2004 and listed on the Tokyo Stock Exchange, the company delivers advanced technology solutions across a range of industries, including fintech, healthcare, and smart manufacturing. In its financial year ended 28 February 2025, Quantum Solutions reported approximately USD 4.7 million in revenue and is currently holdings over several trademarks and patents in games. For more information, please visit: https://www.quantum-s.co.jp/en/corporate Forward-Looking StatementsThis press release contains forward-looking statements based on information currently available to the company and certain assumptions regarding future events and expectations. These statements are subject to various risks and uncertainties—including but not limited to changes in policy, market conditions, technological developments, and regulatory factors—that could cause actual results to differ materially from those expressed or implied in such statements. Existing and prospective investors are advised to consider potential risks carefully and not to place undue reliance on any forward-looking statements contained herein. Such statements speak only as of the date of this release. Unless required by law, the company undertakes no obligation to update or revise any forward-looking statements in light of new information, future events, or other circumstances.For further enquiries, please contact:Hong Kong/International:Mr. Steven TungEmail: steven.tung@quantum-s.co.jpJapan:Ms. Linda PengEmail: linda.peng@quantum-s.co.jp Copyright 2025 ACN Newswire via SeaPRwire.com.
More